GlassScriptPhysician profile
Dean B Ngo
NPI 1982690582
$19,683.80
in general payments reported to CMS, 2019-2025
41 companies · $1,649 in 2025
The $1,649 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,414 · 2021: $1,680 · 2022: $1,650 · 2023: $1,731 · 2024: $1,370 · 2025: $1,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,743 · Travel and Lodging: $6.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,743.07 |
| Travel and Lodging | $6.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $10,516.56 | 2019-2025 | Repatha, Otezla, Evenity |
| Gilead Sciences, INC. | $2,092.96 | 2019-2025 | Vemlidy |
| Lilly USA, LLC | $1,007.70 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $541.18 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $406.22 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $370.51 | 2019-2025 | |
| Novo Nordisk INC | $342.72 | 2021-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.22 | 2019-2023 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $328.93 | 2021-2023 | |
| Glaxosmithkline, LLC. | $320.72 | 2019-2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $297.48 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sunovion Pharmaceuticals INC. | $295.71 | 2019-2022 | |
| Amarin Pharma, INC. | $275.64 | 2019-2023 | |
| Abbvie INC. | $256.93 | 2019-2025 | |
| Astellas Pharma US INC | $242.73 | 2019-2024 | Veozah |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $205.05 | 2023-2025 | Oxlumo |
| Janssen Pharmaceuticals, INC | $203.07 | 2019-2023 | Xarelto |
| Vanda Pharmaceuticals INC. | $156.94 | 2022-2023 | Hetlioz, Fanapt |
| Stryker Corporation | $149.97 | 2022 | |
| Redhill Biopharma INC. | $136.51 | 2025 | Talicia |
| Leo Pharma INC. | $135.62 | 2023 | Adbry |
| Celgene Corporation | $133.27 | 2019 | |
| Ironwood Pharmaceuticals, INC | $125.00 | 2023 | Linzess |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.23 | 2021-2022 | |
| Kyowa Kirin, INC. | $119.05 | 2023 | Nourianz |
| Dexcom, INC. | $79.76 | 2025 | Dexcom G6 Transmitter |
| Covidien LP | $74.26 | 2019 | |
| Seqirus USA INC | $62.30 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Exact Sciences Corporation | $57.61 | 2023-2024 | Cologuard Collection Kit |
| Radius Health, INC. | $48.33 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $41.55 | 2023 | Nuzyra |
| Shionogi INC | $26.00 | 2025 | Fetroja |
| Eisai INC. | $24.38 | 2022 | |
| Medtronic Vascular, INC. | $23.02 | 2019 | |
| Janssen Biotech, INC. | $22.87 | 2025 | Tremfya |
| Optinose US, INC. | $22.23 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.20 | 2025 | Keveyis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.09 | 2023 | Xifaxan |
| Smith+Nephew, INC. | $18.74 | 2019 | |
| Allergan, INC. | $12.79 | 2019 | |
| Sanofi Pasteur INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.